+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts

Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts

American Journal of Pathology 168(2): 398-409

Chronic cholestatic liver diseases arc characterized by impaired balance between proliferation and death of cholangiocytes, as well as vanishing of bile ducts and liver failure. Ursodeoxycholic acid (UDCA) is a bile acid widely used for the therapy of cholangiopathies. However, little is known of the cytoprotective effects of UDCA on cholangiocytes.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 011824624

Download citation: RISBibTeXText

PMID: 16436655

DOI: 10.2353/ajpath.2006.050126

Related references

Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: Effects on bile formation and liver plasma membranes. Liver 13(4): 193-202, 1993

Protective effects of ursodeoxycholic acid for bile duct cells are not enhanced with colchicine in a murine model of experimental cholestasis. Hepatology 32(4 Pt 2): 496A, October, 2000

Effect of ursodeoxycholic acid administration on the biliary mass of unconjugated bile acids in chronic intrahepatic cholestasis. Hepatology 18(4 PART 2): 297A, 1993

Ursodeoxycholic acid and not tauroursodeoxycholic acid prevents the ethynylestradiol induced intrahepatic cholestasis in rats. Gastroenterology 98(5 PART 2): A651, 1990

Effect of ursodeoxycholic acid udca on pruritus and serum cholesterol levels in patients with cholestasis associated with syndromic paucity of intrahepatic bile ducts alagille syndrome. Hepatology 12(4 PART 2): 994, 1990

Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. Journal of Hepatology 23(3): 283-289, 1995

Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 85(6): 1248-1256, 1983

Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid. Gastroenterology 79(6): 1192-1198, 1980

Ursodeoxycholic acid versus tauroursodeoxycholic acid Crossover study of their absorption and biliary enrichment in man. Hepatology 24(4 PART 2): 372A, 1996

Neither ursodeoxycholic acid nor tauroursodeoxycholic acid protects rabbit hepatocytes from toxic bile acids. Gastroenterology 98(5 PART 2): A600, 1990

Effects of lovastatin , ketoconazole and ursodeoxycholic acid in cholestasis following common bile duct ligation. Gastroenterology 106(4 SUPPL ): A911, 1994

Comparison of the effects of an equal dose of 15 mg/kg/day of chenodeoxycholic and ursodeoxycholic acid on the composition of biliary lipids and acids in the bile in radiotransparent biliary lithiasis. Revista Espanola de Las Enfermedades del Aparato Digestivo 64(4): 261-269, 1983

Tauroursodeoxycholic acid appears more effective than UDCA at displacing hydrophobic bile acids from the bile acid pool of patients with primary biliary cirrhosis. Hepatology 20(4 PART 2): 150A, 1994

Cholesterol crystal onset and growth kinetics of gallbladder bile after administration of tauroursodeoxycholic and ursodeoxycholic acid in man. Journal of Hepatology 18(SUPPL 1): S90, 1993